Business Wire

Knopp Biosciences to Present Data on Its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference

Share

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the company will present its precision medicine Kv7 activator program for the treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference, to be held in Miami, FL on May 22-24. KCNQ2-NEE, a rare genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and abnormal brain development.

Presentation Title: Targeting Kv7.2/7.3 Activators for the Treatment of KCNQ2-NEE

Speaker: Steven Dworetzky, PhD, Chief Scientific Officer, Knopp Biosciences

Date & Time: May 24, 2019, 10:00 am Eastern Time

Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and cardiovascular conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.

Knopp's Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Media inquiries:
James Heins
james.heins@icrinc.com
646-277-8251

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sofinnova Partners Raises €333 Million Capital IX Early-Stage Healthcare Fund17.10.2019 06:00:00 CESTPress release

Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the close of its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its platform of life sciences funds. Pursuing the strategy it has consistently applied over the years for its flagship early-stage Capital funds, Sofinnova Capital IX will invest in the healthcare industry and more specifically in the biopharmaceutical and medical device sectors. Sofinnova Partners will seek to invest as a founding and lead investor in start-ups and corporate spin-offs, and focus on therapeutic, paradigm-shifting technologies and products alongside visionary entrepreneurs. Sofinnova Capital IX will invest about two thirds of its funds in European companies, and one third outside of Europe, primarily in Nort

Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream16.10.2019 19:18:00 CESTPress release

The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201 , a multimedia global pandemic exercise on Friday, Oct. 18, 2019, in New York City. The public may register and participate in the simultaneous virtual exercise in English, 8:50 a.m.-12:30 p.m. EDT at centerforhealthsecurity.org/event201/. The exercise underscores the need for global public-private cooperation to mitigate economic and societal impacts of severe pandemics. In recent years, the world has seen a growing number of epidemic events, about 200 per year, which strain limited resources. A large global pandemic would be disruptive to health, economies, and society. Economic studies show that pandemics could be the cause of an average annual economic loss of 0.7% of global GDP—or $570 billion. Event 201, played by 15 leaders of businesses, governments, and public health, will illustrate realistic policy problems that must be addressed under pres

Murray Energy Corporation Extends Forbearance Agreements with its Lenders and Elects Not to Make Interest Payments to Noteholders16.10.2019 17:47:00 CESTPress release

As previously disclosed, on October 2, 2019 Murray Energy Corporation (“Murray Energy” or “the Company”) entered into forbearance agreements with lenders holding in excess of 50% of outstanding loans under its Superpriority Credit and Guaranty Agreement and with lenders holding in excess of 50% of outstanding loans under its ABL and FILO credit facilities. Under the terms of the forbearance agreements, the lenders agreed to forbear from exercising any and all remedies available to them in respect of any event of default arising from the missed amortization and interest payments due on September 30, 2019. On October 15, 2019, Murray Energy and its lenders amended the previously disclosed forbearance agreements, extending the forbearance period through 11:59 p.m. (New York time) on October 28, 2019, unless further extended. The forbearance agreements will terminate upon the earlier of the end of the forbearance period or the occurrence of a specified forbearance termination event. With d

Tealium Expands Leadership Team, Appoints World-Class Marketing Executive as CMO16.10.2019 15:37:00 CESTPress release

Tealium, the trusted leader in real-time customer data orchestration, today announced that Heidi Bullock has joined the company as Chief Marketing Officer (CMO). Bullock previously served as CMO at Engagio, and prior to that as Group Vice President of Global Marketing at Marketo. “We are thrilled to have Heidi joining the executive team at Tealium,” said Jeff Lunsford, Chief Executive Officer (CEO) of Tealium. “She is a fantastic addition, not only due to her extensive knowledge in marketing but also her impressive leadership experience in building and scaling high-performance marketing teams. Heidi will undoubtedly help us expand our market position in a high growth market and continue to solidify us as a global leader in the industry.” Most recently she was the CMO of Engagio, where she was responsible for the go-to-market strategy, product marketing, internal sales, corporate communications, and helping create the ABM Automation category. Prior to Engagio, Heidi was the Group Vice P

JD Events: Plant Based World Launches in the UK16.10.2019 14:44:00 CESTPress release

Following the huge success of the Plant Based World Conference & Expo in New York, organiser JD Events is delighted to announce the launch of Plant Based World Europe in London in 2020. The UK is Europe’s largest market for plant-based foods, valued at £470m versus $4.5bn in the US, and is growing at an exponential rate. Adoption of a plant-based lifestyle is sweeping the globe as people everywhere are becoming aware of the human health, environmental and ethical implications of consuming more plant-based products. One in six food products launched in the UK in 2018 carried a vegan claim. “The fundamental shift away from animal product consumption towards more wholesome, plant-based options is our opportunity as a society to create a healthier world for future generations”, commented Ben Davis, Content & Communications Director, Plant Based World Conference & Expo. “Our goal at PBW is to accelerate this shift by providing a professional platform for the global plant-based market to blo

European DataWarehouse Releases Updated Version of EDITOR as European Commission Publishes RTS on Disclosure16.10.2019 13:31:00 CESTPress release

The European Commission today published the Regulatory Technical Standards (RTS) on Disclosure Requirements, a key building block of the EU Securitisation Regulation (EU) 2017/2402. Once the European Parliament and the Council endorse the RTS, it will be published in the Official Journal of the European Union (EU). In the absence of objections, the new disclosure requirements, including ESMA’s new reporting templates, will come into force in Q1 2020. European DataWarehouse (ED) has been preparing for the implementation of the new disclosure regime since the Securitisation Regulation entered into force on 17 January 2018, and already offers a number of related services for originators, sponsors and SSPEs. Notably, ED launched a new version of its web-based reporting solution, EDITOR, earlier this week. EDITOR covers all reporting requirements for both public and private ABS and ABCP transactions, including the ability to submit reporting templates in ESMA’s prescribed XML format. Dr. Ch